References

rpcardio

Rational Pharmacotherapy in Cardiology

Рациональная Фармакотерапия в Кардиологии

1819-64462225-3653

«SILICEA-POLIGRAF» LLC

10.20996/1819-6446-2022-02-12

rpcardio-2664

Research Article

CURRENT QUESTIONS OF CLINICAL PHARMACOLOGY

АКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИ

Cardiovascular Effects of Metformin

Кардиоваскулярные эффекты метформина

Курманбекова

Б. Т.

Kurmanbekova

B. T.

Курманбекова Бермет Темирбековна.

Бишкек.

Bermet T. Kurmanbekova.

Bishkek.

bermet101191@gmail.com

Норузбаева

А. М.

Noruizbaeva

A. M.

Норузбаева Айгуль Мукашевна.

Бишкек.

Aigul M. Noruzbaeva.

Bishkek.

Национальный центр кардиологии и терапии имени академика М.М. МиррахимоваКыргызстанNational Center of cardiology and internal medicine named after academician M.MirrakhimovKyrgyzstan

2022

03032022

18197102

2022

Курманбекова Б.Т., Норузбаева А.М.

Kurmanbekova B.T., Noruizbaeva A.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.rpcardio.online/jour/article/view/2664

Type 2 diabetes mellitus is one of the most important independent risk factors for the development, progression and mortality from cardiovascular diseases (CVD). The world communities are faced with the question of developing the optimal management tactics for such comorbidity patients. Thus, the prescribed drug should not only have an adequate hypoglycemic effect, but also have a number of cardioprotective properties, be safe in patients with CVD, and possibly even improve the prognosis and reduce mortality rates. This review is devoted to a representative of the biguanide class - metformin, which is one of the earliest and most effective antihyperglycemic drugs, both as monotherapy and in combination with other antihyperglycemic drugs and insulin; while the evidence base for its cardiovascular profile is only gaining momentum. Thus, the purpose of this review is to highlight the cardiovascular effects of metformin in the context of recent research.

Сахарный диабет 2 типа является одним из важнейших независимых факторов риска развития, прогрессирования и смертности от сердечно-сосудистых заболеваний (ССЗ). Перед мировыми сообществами встает вопрос о разработке оптимальной тактики ведения больных с данной коморбидностью. Так, назначаемый препарат должен оказывать не только адекватный гипогликемический эффект, но и обладать рядом кардиопротективных свойств, быть безопасным у больных ССЗ и, возможно, улучшать прогноз и снижать показатели смертности. Настоящий обзор посвящен представителю класса бигуанидов – метформину, являющемуся одним из самых первых и наиболее эффективных гипогликемических препаратов как в качестве монотерапии, так и в комбинации с другими препаратами данной группы и инсулином, в то время как доказательная база в отношении его сердечно-сосудистого профиля только набирает обороты. Таким образом, цель настоящего обзора – описать кардиоваскулярные эффекты метформина в контексте последних исследований.

метформинсердечно-сосудистые заболеваниякардиопротективные свойства

metformincardiovascular diseasecardioprotective properties

References1

Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-701. DOI:10.2337/dci18-0033.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-85. DOI:10.1007/s00125-017-4342-z.

Wang YW, He SJ, Feng X, et al. Metformin: a review of its potential indicators. Drug Des Devel Ther. 2017;11:2421-9. DOI:10.2147/DDDT.S141675.

Luo F, Das A, Chen J, et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol. 2019;18(1):54. DOI:10.1186/s12933-019-0860-y.

Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55(2):496-505. DOI:10.2337/diabetes.55.02.06.db05-1064.

Heidari B, Lerman A, Lalia AZ, et al. Effect of metformin on microvascular endothelial function in polycystic ovary syndrome. Mayo Clin Proc. 2019;94(12):2455-66 DOI:10.1016/j.mayocp.2019.06.015.

Bloomgarden ZT. Glycemic Control in Diabetes: a tale of three studies. Diabetes Care. 2008;31(9):1913-19. DOI:10.2337/dc08-zb09.

Eriksson L, Nystrom T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovasc Diabetol. 2014;13:152. DOI:10.1186/PREACCEPT-9581518081340209.

Dong Y, Zhang M, Liang B, et al. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation. 2010;121(6):792-803. DOI:10.1161/CIRCULATIONAHA.109.900928.

Faxon DP, Fuster V, Libby P, et al. Atherosclerotic vascular disease conference: writing group III: pathophysiology. Circulation. 2004;109(21):2617-25. DOI:10.1161/01.CIR.0000128520.37674.EF.

Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852-66. DOI:10.1161/CIRCRESAHA.114.302721.

Song P, Zhou Y, Coughlan KA, et al. Adenosine monophosphate-activated protein kinase-alpha2 deficiency promotes vascular smooth muscle cell migration via S-phase kinase-associated protein 2 upregulation and E-cadherin downregulation. Arterioscler Thromb Vasc Biol. 2013;33(12):2800-9. DOI:10.1161/ATVBAHA.113.301869.

Zhou DM, Ran F, Ni HZ, et al. Metformin inhibits high glucose-induced smooth muscle cell proliferation and migration. Aging (Albany NY). 2020;12(6):5352-61. DOI:10.18632/aging.102955.

Fan Z, Yang J, Yang J, et al. HMGB1: A promising therapeutic approach for atherosclerosis. Int J Cardiol. 2016;202:507-8. DOI:10.1016/j.ijcard.2015.09.101.

Legein B, Temmerman L, Biessen EA, Lutgens E. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci. 2013;70(20):3847-69. DOI:10.18632/oncotarget.23208.

Li SN, Wang X, Zeng QT, et al. Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. Heart Vessels. 2009;24(6):446-53. DOI:10.1007/s00380-008-1137-7.

Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26(3):611-7. DOI:10.1161/01.ATV.0000201938.78044.75.

Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006;47(6):1183-8. DOI:10.1161/01.HYP.0000221429.94591.72.

Rena G, Lang CC. Repurposing metformin for cardiovascular disease. Circulation. 2018;137(5):422-4. DOI:10.1161/CIRCULATIONAHA.117.031735.

Ketelhuth DFJ, Lutgens E, Bäck M, et al. Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovasc Res. 2019;115(9):1385-92. DOI:10.1093/cvr/cvz166.

Rutter M.K., Nesto R.W. The BARI 2D Study: a randomized trial of therapies for type 2 diabetes and coronary artery disease Diab Vasc Dis Res. 2010;7(1):69-72. DOI:10.1177/1479164109354145.

de Jager J, Kooy A, Schalkwijk C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes mellitus: a randomized controlled trial. J Intern Med. 2014;275(1):59-70. DOI:10.1111/joim.12128.

Sirtori CR, Catapano A, Ghiselli GC, et al. Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits. Atherosclerosis. 1977;26(1):79-89. DOI:10.1016/0021-9150(77)90142-3.

Forouzandeh F, Salazar G, Patrushev N, et al. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):e001202. DOI:10.1161/JAHA.114.001202.

Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221-8. DOI:10.1111/j.1463-1326.2010.01349.x.

Cai Z, Ding Y, Zhang M, et al. Ablation of adenosine monophosphate-activated protein kinase alpha1 in vascular smooth muscle cells promotes diet-induced atherosclerotic calcification in vivo. Circ Res. 2016;119(3):422-33. DOI:10.1161/CIRCRESAHA.116.308301.

Yu XH, Fu YC, Zhang DW, et al. Foam cells in atherosclerosis. Clin Chim Acta. 2013; 424:245-52. DOI:10.1016/j.cca.2013.06.006.

Vasamsetti SB, Karnewar S, Kanugula AK, et al. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015;64(6):2028-41. DOI:10.2337/db14-1225.

Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. DOI:10.1016/S0140-6736(12)60367-5.

Xu T, Brandmaier S, Messias AC, et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015;38(10):1858-67. DOI:10.2337/dc15-0658.

Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597-609. DOI:10.1016/S2213-8587(17)30194-8.

Lunder M, Janic M, Japelj M, et al. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):153. DOI:10.1186/s12933-018-0797-6.

Chan CW, Yu CL, Lin JC, et al. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol. 2018;17(1):20. DOI:10.1186/s12933-018-0663-6.

Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616-25. DOI:10.1001/archinternmed.2009.20.

Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304-11. DOI:10.2337/dc12-0719.

Preiss D, Lloyd SM, Ford I, et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2(2):116-24. DOI:10.1016/S2213-8587(13)70152-9.

Rosenson RS, Brewer HB, Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48-60. DOI:10.1038/nrcardio.2015.124.

Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383-93. DOI:10.1056/NEJMoa1409065.

Goldberg RB, Temprosa M, Mele L, et al. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. Metabolism. 2016;65(5):764-75. DOI:10.1016/j.metabol.2015.11.011.

Matsuki K, Tamasawa N, Yamashita M, et al. Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis. 2009;206(2):434-8. DOI:10.1016/j.atherosclerosis.2009.03.003.

Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345-61. DOI:10.1093/eurheartj/ehr112.

Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-74. DOI:10.1056/NEJMoa1001282.

Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123-33. DOI:10.1056/NEJMoa1510926.

Geerling JJ, Boon MR, van der Zon GC, et al. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes. 2014;63(3):880-91. DOI:10.2337/db13-0194.

Li R, Chen LZ, Zhao W, et al. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway. Biochem Biophys Res Commun. 2016;478(3):1173-8. DOI:10.1016/j.bbrc.2016.08.087.

Luo F, Guo Y, Ruan GY, et al. Estrogen lowers triglyceride via regulating hepatic APOA5 expression. Lipids Health Dis. 2017;16(1):72. DOI:10.1186/s12944-017-0463-0.

Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256(1):1-14. DOI:10.1111/j.1365-2796.2004.01328.x.

DiBona PJ. Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats. Hypertension. 1996;27(3 Pt 2):619-25. DOI:10.1161/01.HYP.27.3.619.

Wulffele MG, Kooy A, Lehert P, et al. Does metformin decrease blood pressure in patients with type 2 diabetes mellitus intensively treated with insulin? Diabet Med. 2005;22(7):907-13. DOI:10.1111/j.1464-5491.2005.01554.x.

Zhou L, Liu H, Wen X, et al. Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials. J Hypertens. 2017;35(1):18-26. DOI:10.1097/HJH.0000000000001119.

Jadhav S, Ferrell W, Greer IA, et al. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2006;48(5):956-63. DOI:10.1016/j.jacc.2006.04.088.

Wong AKF, Symon R, Adzjali M, et al. Metformin in insulin resistant LV dysfunction, a double blind placebo controlled trial. Heart. 2010;96(Suppl 1):A39-A40. DOI:10.1136/hrt.2010.195966.15.

Lexis CP, van der Horst IC, Lipsic E, et al. Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial. Cardiovasc Drugs Ther. 2012;26(5):417-26. DOI:10.1007/s10557-012-6413-1.

Mohan M, Al-Talabany S, McKinnie A, et al. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J. 2019;40(41):3409-17. DOI:10.1093/eurheartj/ehz203.

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT) [cited 2020 Aug 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02915198.

Hao Z, Liu Y, Liao H, et al. Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration. Exp Clin Endocrinol Diabetes. 2016;124(4):246-50. DOI:10.1055/s-0035-1569364.

Meaney E, Vela A, Samaniego V, et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol. 2008;35(8):895-903. DOI:10.1111/j.1440-1681.2008.04920.x.

Han Y, Xie HLiu Y, et al. Effect of Metformin on All-Cause and Cardiovascular Mortality in Patients With Coronary Artery Diseases: A Systematic Review and an Updated Meta-Analysis. Cardiovasc Diabetol. 2019;18(1):96. DOI:10.1186/s12933-019-0900-7.

The authors declare that there are no conflicts of interest present.